UNSW Sydney and the Garvan Institute of Medical Research researchers will lead the program, thanks to a $3.75 million grant from the Cancer Institute NSW
Share A national clinical trial program will test promising new targeted therapies for pancreatic cancer, one of the deadliest forms of cancers of which more than 3000 cases are diagnosed annually in Australia. The clinical trial program (MoST–P), led by researchers and clinicians at UNSW and the Garvan Institute, will provide patients with access to either targeted therapies matched to the genomic signature of their individual tumour, or targeted to the tumour environment. UNSW Dean of Medicine & Health, Professor Vlado Perkovic said the grant could lead to better outcomes for pancreatic c...
Source: indiaeducationdiary.in
